CLEVELAND, Sept. 30 /PRNewswire/ -- Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30(R) (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators. Grants focus on researching the effects of GanedenBC30 on human immune cells. Previous studies have demonstrated the ability of GanedenBC30 to modulate numerous human immune cells, both in vitro and in vivo.
To be eligible, investigators must have a full-time faculty appointment at a research institution or medical school. Applicants must have interest in studying the effects of GanedenBC30 on human immune cells, as well as the capacity to conduct such research.
Two grants will be funded at a maximum of $15,000 for each project. Applicants will be expected to submit a budget outlining how the funds will be used. A meeting with Ganeden's Scientific Board will be required prior to the start of the research, as well as following the research to present the results. Travel for these meetings will be subsidized above the grant amount.
Applications will be reviewed by:
Grant applications will be judged on quality of the proposed experimental design, originality of the proposal, evidence of the applicant's ability to conduct the proposed research, and relevance of the proposed research to the health of the general population.
Please contact Dr. David Keller at keller@ganedenbiotech.com for all requests and submission of applications. The deadline for applications is December 31, 2009.
"Ganeden Biotech is happy to announce these grants to early investigators," said Ganeden Biotech CSO and co-founder Sean Farmer. "We believe that research is core to the probiotics industry, and that these grants will enable early investigators to add to the current body of research demonstrating the health benefits of probiotics."
About Ganeden Biotech
Founded in 1996, Ganeden Biotech Inc. is a private company based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage and Sustenex brands. It also licenses its patented probiotic bacteria, GanedenBC30, for use in commercial food and beverage applications as well as in medical foods and dietary supplements. GanedenBC30 was found to be Generally Recognized As Safe (GRAS) by an independent expert panel assembled to assess its safety in use as a food ingredient. Digestive Advantage and Sustenex are available at over 40,000 retailers nationwide including Wal-Mart, CVS/pharmacy, Walgreens, Rite-Aid, Stop & Shop, Giant, Publix, Kroger, and Target. For more information, visit www.digestiveadvantage.com, www.sustenex.com, or www.ganedenlabs.com.
SOURCE Ganeden Biotech Inc.
CONTACT: Jennifer Tilliss of Linhart PR, +1-303-951-2566,
jtilliss@linhartpr.com, for Ganeden Biotech Inc.
Web site: http://www.ganedenlabs.com/
http://www.digestiveadvantage.com/
http://www.sustenex.com/
